Abstract
The present meta-analysis pooled data from 5 double-blind, placebo-controlled studies in 432 patients with dyslipidemia treated with various doses of extended-release niacin. Data were analyzed for possible gender differences in response to treatment. At all doses, mean decreases in low-density lipoprotein cholesterol were greater in women than in men; differences were significant at doses of 1,000 mg (6.8% vs 0.2%, p = 0.006), 1,500 mg (11.3% vs 5.6%, p = 0.013), 2,000 mg (14.8% vs 6.9%, p = 0.010), and 3,000 mg (28.7% vs 17.7%, p = 0.006). Decreases in triglyceride levels also tended to be greater in women than in men but reached significance only at the 1,500-mg dose (28.6% vs 20.4%, p = 0.040). No similar trends or significant gender differences were noted in levels of lipoprotein(a) and high-density lipoprotein cholesterol. This meta-analysis confirms that women respond as well as men, and possibly slightly better, to treatment with extended-release niacin and that it is a safe and effective treatment option for women with dyslipidemia.
References
Jan 1, 1994·European Journal of Clinical Pharmacology·A FiguerasJ R Laorte
Sep 29, 1998·Metabolism: Clinical and Experimental·R H KnoppS Marcovina
Oct 7, 1998·The American Journal of Cardiology·J R GuytonC M O'Connor
Nov 24, 1998·Journal of Clinical Pharmacology·C TranN H Shear
Jan 23, 1999·The American Journal of Cardiology·A C Goldberg
Apr 27, 2000·The American Journal of Cardiology·A GoldbergP Samuel
Jul 19, 2002·Archives of Internal Medicine·Scott M GrundyUNKNOWN Diabetes Multicenter Research Group
Citations
Jun 10, 2010·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Yunsuk KohDavid L Nichols
Jul 16, 2005·Journal of Periodontology·Rodrigo F NeivaHom-Lay Wang
Jul 16, 2011·Expert Opinion on Pharmacotherapy·Altan Onat
May 20, 2008·Current Medical Research and Opinion·Sachin J Kamal-BahlCharles E Wentworth
Dec 20, 2007·Nursing for Women's Health·Susan J AppelEmily J Jones
Apr 3, 2010·Mayo Clinic Proceedings·Terry A Jacobson
Feb 27, 2009·Clinical Therapeutics·Sachin Kamal-BahlBaishali M Ambegaonkar
Feb 1, 2011·Archives of Physical Medicine and Rehabilitation·Mark S NashWilliam A Bauman
Dec 15, 2005·Heart, Lung & Circulation·Avni Sali, Luis Vitetta
Feb 21, 2006·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·R AccinniM Gorini
Oct 1, 2005·The American Journal of Medicine·Robert S Rosenson
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Daniel Schneider, Judith Hsia
Nov 1, 2005·Journal of the American College of Cardiology·Vera Bittner
Jun 16, 2017·The Cochrane Database of Systematic Reviews·Stefan SchandelmaierAlain J Nordmann
Dec 21, 2006·Toxicologic Pathology·Akinori ShimadaTakehito Morita
Jan 6, 2006·Drugs·Paul L McCormack, Gillian M Keating
Apr 25, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerMichael Davidson
Oct 3, 2006·Journal of Lipid Research·Eric E Schadt, Pek Y Lum
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis